Glen Eagle Advisors’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $328K | Sell |
5,400
-363
| -6% | -$21.2K | 0.05% | 218 |
|
|
2025
Q4 | $311K | Sell |
5,763
-2,731
| -32% | -$131K | 0.04% | 220 |
|
|
2025
Q3 | $383K | Buy |
8,494
+96
| +1% | +$4.48K | 0.05% | 203 |
|
|
2025
Q2 | $389K | Sell |
8,398
-1,792
| -18% | -$88K | 0.06% | 181 |
|
|
2025
Q1 | $622K | Buy |
10,190
+6,761
| +197% | +$394K | 0.1% | 130 |
|
|
2024
Q4 | $194K | Sell |
3,429
-28
| -0.8% | -$1.56K | 0.03% | 241 |
|
|
2024
Q3 | $179K | Hold |
3,457
| – | – | 0.03% | 255 |
|
|
2024
Q2 | $144K | Sell |
3,457
-539
| -13% | -$24.1K | 0.03% | 262 |
|
|
2024
Q1 | $217K | Sell |
3,996
-52
| -1% | -$2.65K | 0.04% | 228 |
|
|
2023
Q4 | $208K | Sell |
4,048
-13
| -0.3% | -$682 | 0.04% | 226 |
|
|
2023
Q3 | $236K | Buy |
4,061
+648
| +19% | +$39.7K | 0.05% | 206 |
|
|
2023
Q2 | $218K | Sell |
3,413
-409
| -11% | -$27.4K | 0.05% | 220 |
|
|
2023
Q1 | $265K | Sell |
3,822
-65
| -2% | -$4.58K | 0.07% | 197 |
|
|
2022
Q4 | $280K | Sell |
3,887
-37
| -0.9% | -$2.79K | 0.08% | 182 |
|
|
2022
Q3 | $279K | Sell |
3,924
-665
| -14% | -$48.2K | 0.08% | 175 |
|
|
2022
Q2 | $353K | Buy |
4,589
+665
| +17% | +$50.6K | 0.1% | 161 |
|
|
2022
Q1 | $287K | Buy |
3,924
+1,064
| +37% | +$71.4K | 0.07% | 192 |
|
|
2021
Q4 | $178K | Sell |
2,860
-1,581
| -36% | -$92.7K | 0.05% | 223 |
|
|
2021
Q3 | $263K | Hold |
4,441
| – | – | 0.08% | 194 |
|
|
2021
Q2 | $297K | Buy |
4,441
+101
| +2% | +$6.59K | 0.09% | 178 |
|
|
2021
Q1 | $274K | Buy |
4,340
+286
| +7% | +$17.8K | 0.1% | 170 |
|
|
2020
Q4 | $251K | Sell |
4,054
-26
| -0.6% | -$1.6K | 0.1% | 159 |
|
|
2020
Q3 | $246K | Buy |
4,080
+81
| +2% | +$4.88K | 0.11% | 136 |
|
|
2020
Q2 | $235K | Buy |
3,999
+121
| +3% | +$7.24K | 0.12% | 136 |
|
|
2020
Q1 | $216K | Buy |
3,878
+170
| +5% | +$10.4K | 0.15% | 125 |
|
|
2019
Q4 | $238K | Buy |
3,708
+601
| +19% | +$34.4K | 0.13% | 144 |
|
|
2019
Q3 | $158K | Buy |
3,107
+80
| +3% | +$3.76K | 0.1% | 164 |
|
|
2019
Q2 | $137K | Sell |
3,027
-864
| -22% | -$40.2K | 0.09% | 178 |
|
|
2019
Q1 | $186K | Sell |
3,891
-45
| -1% | -$2.24K | 0.14% | 145 |
|
|
2018
Q4 | $205K | Buy |
3,936
+1
| +0% | +$54 | 0.17% | 126 |
|
|
2018
Q3 | $244K | Buy |
3,935
+1
| +0% | +$59 | 0.17% | 125 |
|
|
2018
Q2 | $218K | Sell |
3,934
-61
| -2% | -$3.29K | 0.17% | 131 |
|
|
2018
Q1 | $253K | Sell |
3,995
-150
| -4% | -$9.65K | 0.21% | 111 |
|
|
2017
Q4 | $254K | Buy |
4,145
+234
| +6% | +$14.6K | 0.22% | 108 |
|
|
2017
Q3 | $249K | Buy |
3,911
+749
| +24% | +$43.7K | 0.23% | 106 |
|
|
2017
Q2 | $176K | Sell |
3,162
-53
| -2% | -$2.88K | 0.14% | 134 |
|
|
2017
Q1 | $175K | Sell |
3,215
-544
| -14% | -$29.8K | 0.15% | 133 |
|
|
2016
Q4 | $220K | Buy |
+3,759
| New | +$206K | 0.2% | 120 |
|
Other funds holding BMY
VCM
VPM
Glen Eagle Advisors's BMY Position: Q1 2026 in Review
Glen Eagle Advisors reduced its Bristol-Myers Squibb (BMY) stake by 6.3% in Q1 2026, selling an estimated $21.2K and leaving 5,400 shares worth $328K. The position accounts for 0.05% of the portfolio, ranked #218.
Glen Eagle Advisors first reported a position in BMY in Q4 2016 and has held it in 38 quarters since. The position peaked at $622K in Q1 2025. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Glen Eagle Advisors held 5,400 shares of Bristol-Myers Squibb worth $328K as of Q1 2026.
- Glen Eagle Advisors sold 363 Bristol-Myers Squibb shares in Q1 2026, an estimated $21.2K.
- Bristol-Myers Squibb made up 0.05% of Glen Eagle Advisors's portfolio in Q1 2026, its #218 holding.
- Glen Eagle Advisors first reported a position in Bristol-Myers Squibb in Q4 2016 and has held it in 38 quarters since.
- Glen Eagle Advisors's Bristol-Myers Squibb position peaked at $622K in Q1 2025.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Glen Eagle Advisors's 13F filing for Q1 2026, filed 15 May 2026.